Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2021-04-26 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 17th meeting of the 7th Board of Directors of Beijing SL Pharmaceutical Co., Ltd. It includes approvals of various reports such as the 2020 Board Work Report, 2020 General Manager Work Report, 2020 Financial Final Accounts Report, 2020 Profit Distribution Plan, 2020 Annual Report and Summary, 2021 Q1 Report, 2020 Internal Control Evaluation Report, and 2020 Social Responsibility Report. It also covers proposals for reappointment of auditors, related party transactions, short-term risk investment, nomination of new board members, amendments to company articles and rules, and the scheduling of the 2020 Annual General Meeting. The document is a formal announcement of board meeting resolutions and does not contain the full reports themselves but references where they can be found. The content is consistent with a Board/Management Information filing, as it announces board decisions and management reports for shareholder and regulatory information. It is not the full Annual Report (10-K), nor a simple announcement of report publication (RPA), but a comprehensive board meeting resolution announcement. Therefore, the appropriate classification is MANG (Board/Management Information). Confidence is high given the detailed nature and content of the document.
2021-04-26 Chinese
北京双鹭药业股份有限公司控股子公司管理制度（2021.04）
Board/Management Information Classification · 95% confidence The document is titled '北京双鹭药业股份有限公司 控股子公司管理制度' which translates to 'Beijing SL Pharmaceutical Co., Ltd. Controlling Subsidiary Management System'. It is a detailed internal management system document outlining governance, management, financial, administrative, human resources, reporting, audit supervision, and other operational procedures for the company's controlling subsidiaries. The document references compliance with laws, regulations, and stock exchange rules, and it is approved by the company's board of directors. It does not contain financial statements, earnings data, voting results, or any form of report publication announcement. It is a governance and management policy document related to board and management structure and control over subsidiaries. Therefore, the most appropriate classification is 'Board/Management Information (MANG)'. The document length (6402 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive governance document.
2021-04-26 Chinese
北京双鹭药业股份有限公司董事、监事及高级管理人员持有及买卖本公司股份的专项管理制度(2021.04)
Director's Dealing Classification · 95% confidence The document is a detailed internal policy titled '董事、监事和高级管理人员持有及买卖本公司股份的专项管理制度' (Special Management System for Directors, Supervisors and Senior Management Personnel Holding and Trading the Company's Shares) issued by Beijing Shuanglu Pharmaceutical Co., Ltd. It outlines rules and regulations governing the holding and trading of company shares by directors, supervisors, and senior management, including disclosure requirements, restrictions, penalties, and compliance with relevant laws and stock exchange regulations. The content focuses on insider trading restrictions, reporting obligations, and management of share transactions by company insiders. This type of document is a regulatory compliance and governance-related filing concerning insider share dealings by company executives and directors. It is not a financial report, earnings release, or announcement of voting results. It is not a simple announcement but a substantive policy document. The document fits best under the category 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives and related management rules.
2021-04-26 Chinese
独立董事提名人声明（一）
Board/Management Information Classification · 95% confidence The document is a formal statement nominating an independent director candidate for the company's board. It details the nominee's qualifications, compliance with various regulatory requirements, and declarations regarding independence and eligibility. There is no financial data, no discussion of financial results, no mention of annual or interim reports, earnings, or other financial filings. The content focuses exclusively on board/management information, specifically the nomination of a board member. Therefore, the document fits the category of Board/Management Information (MANG). The document length (5763 characters) supports it being a full statement rather than a brief announcement or certification.
2021-04-26 Chinese
独立董事提名人声明（二）
Board/Management Information Classification · 95% confidence The document is a public statement nominating an individual as an independent director candidate for the company's board. It contains detailed declarations about the nominee's qualifications, compliance with various regulatory requirements, and independence criteria. There is no financial data, no discussion of financial results, no mention of shareholder voting results, and no indication of a meeting presentation or report publication. The content is focused on board/management information, specifically the nomination of a board member. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length (5758 characters) and detailed content support this classification with high confidence.
2021-04-26 Chinese
独立董事候选人声明（钱令嘉）
Board/Management Information Classification · 95% confidence The document is a detailed declaration by an independent director candidate of Beijing Shuanglu Pharmaceutical Co., Ltd. It contains statements about the candidate's qualifications, compliance with relevant laws and regulations, and independence criteria. There are no financial statements, earnings data, or management discussions. The content is focused on the candidate's eligibility and compliance for a board position, which aligns with announcements or information related to board or management changes. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is over 6,000 characters and contains substantive content, not just a brief announcement or certification, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2021-04-26 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.